(0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Sheraton Philadelphia University City

2017 年 10 月 23 日 7:30 上午 - 2017 年 10 月 26 日 5:00 下午

3549 Chestnut Street, Philadelphia, PA 19104

Regulatory Affairs: The IND, NDA, and Postmarketing

概览

Learn about FDA regulations and expectations for the content, submission and review of INDs/NDAs, and the importance of regulatory strategy. This comprehensive course employs a blend of real-world and interactive lectures, workshops, and online precourse modules. This basic to intermediate level training course focuses on prescription drugs and well-characterized biological products.  The requirements specific to generic drugs, biosimilars, devices, and OTC monograph products are not covered in detail.

“The course is replete with information that has swirled around me since starting work in RA but that had remained elusive due to the narrow nature of my day-to-day. The course provided structure for this swirling information, which gave me a clear picture of how the pieces fit together. I'd definitely recommend it to anybody who has worked in regulatory affairs for a few years and/or has experience in only one area of RA but desires to understand the whole picture.”

-Previous Participant

内容纲要

  • Fundamentals of the Investigational New Drug (IND) and New Drug Application (NDA) Processes
    • Preparation
    • Content
    • Maintenance and updates
    • Strategy
  • What to expect at meetings and in other interactions with FDA
  • Regulatory Requirements of Prescription Drug Labeling and Advertising
  • Postmarketing Requirements

谁应该参加？

  • Regulatory affairs professionals new to the IND/NDA processes
  • Clinical research and development professionals
  • Biostatisticians
  • Basic researchers
  • Quality and manufacturing professionals
  • Medical writers
  • Business professionals
  • Project managers

 

学习目标

At the conclusion of this activity, participants should be able to:

  • Explain the importance of incorporating regulatory strategy into the drug development plan
  • Recognize content and format requirements for INDs/NDAs in the Common Technical Document (CTD) Format
  • Communicate the requirements for submitting INDs/NDAs and amendments and supplements
  • Describe the FDA review processes for evaluating INDs/NDAs
  • Define NDA post-approval responsibilities and requirements
  • Identify regulatory mechanisms to facilitate and expedite new drug development
  • State how to report adverse events in accordance with current FDA regulations 
  • Apply formal meeting principles and practices when interacting with the FDA
  • Outline the regulatory requirements for prescription drug labeling and advertising

 

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表，了解DIA的观点和事件。